← Back to Search

Alkylating agent

Docetaxel + Cisplatin + Amifostine for Lung Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Performance status ECOG 0 or 1
Age over 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well combining docetaxel, cisplatin, and amifostine works in treating patients with non-small cell lung cancer.

Who is the study for?
Adults over 18 with advanced non-small cell lung cancer that can't be removed by surgery. They must have a good performance status, meaning they're fairly active and able to care for themselves. Participants should not be pregnant, must use contraception if fertile, and cannot have severe peripheral neuropathy or recent cisplatin treatment.Check my eligibility
What is being tested?
The trial is testing the combination of chemotherapy drugs docetaxel and cisplatin with amifostine, which may protect healthy cells from chemo side effects. It's for patients with advanced lung cancer who've tried other treatments without success.See study design
What are the potential side effects?
Possible side effects include damage to normal cells leading to low blood counts, risk of infection, fatigue, nausea, vomiting, kidney problems from cisplatin; hair loss and allergic reactions from docetaxel; and possible skin rash or drop in blood pressure from amifostine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am over 18 years old.
Select...
My kidneys work well, with a creatinine clearance of 60 mL/min or more.
Select...
My lung cancer cannot be removed with surgery.
Select...
I do not have severe numbness or pain in my hands or feet.
Select...
My liver function tests are within the required limits.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,183 Previous Clinical Trials
3,167,971 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,660 Previous Clinical Trials
40,924,272 Total Patients Enrolled
Joan H. Schiller, MDStudy ChairUniversity of Wisconsin, Madison
5 Previous Clinical Trials
935 Total Patients Enrolled

Media Library

Cisplatin (Alkylating agent) Clinical Trial Eligibility Overview. Trial Name: NCT00004264 — Phase 1 & 2
Lung Cancer Research Study Groups:
Lung Cancer Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT00004264 — Phase 1 & 2
Cisplatin (Alkylating agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004264 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for new participants to join the experiment?

"The information available on clinicaltrials.gov discloses that this trial, which was initially published on July 1st 1997, is not presently recruiting patients. Despite this, there are a whopping 1670 other studies looking for recruits at the moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
1997. "Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004264.
All > Lung > Sclc
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top